DSIP vs Semax: A Canadian Research Comparison of Sleep and Cognitive Peptides

The comparison between DSIP and Semax is not as common as Selank versus Semax, but it is equally important for Canadian researchers who need to match a peptide to a specific experimental question. Both compounds are Russian-origin research peptides with long publication histories. Both appear in cognitive and neuroscience supplier catalogues. Both are small enough to be synthetically accessible and analytically straightforward. But their biological targets, primary literatures, and optimal research contexts are almost entirely non-overlapping. A researcher who assumes that because both are "Russian nootropics" they can be substituted for one another risks building a protocol around the wrong mechanism.

DSIP — delta sleep-inducing peptide — is a nonapeptide originally isolated from cerebral venous blood during sleep. Its literature centres on sleep-phase modulation, HPA-axis regulation, endocrine rhythm normalisation, and stress-recovery physiology. Semax is a heptapeptide analogue of the ACTH(4-10) fragment, with a literature centred on neuroprotection, BDNF/trkB signalling, cerebral ischemia recovery, and attention-related plasticity. The two compounds do not share a receptor, a signalling pathway, or a primary endpoint. They belong in different experimental designs.

This guide is written for Canadian labs that need a clear, evidence-based framework for choosing between DSIP and Semax. It is not medical advice, not a wellness recommendation, and not a consumer buying guide. All compounds discussed here are research-use-only. Canadian researchers should verify that their protocols comply with institutional ethics, biosafety standards, and the Food and Drugs Act.

A fast summary before the details#

If a Canadian researcher needs the short version first:

Choose DSIP when the experimental question involves sleep architecture, circadian-rhythm modulation, HPA-axis dynamics, stress-recovery physiology, or endocrine timing. DSIP is the peptide most closely aligned with sleep-phase research, deep-sleep maintenance, and the transition between wake and sleep states. It is not a general sedative and should not be modelled as one.

Choose Semax when the experimental question involves neuroprotection, BDNF/trkB signalling, cerebral ischemia recovery, attention-related plasticity, or cognitive enhancement after injury. Semax is the peptide most closely aligned with neurotrophin-centred plasticity and post-ischemic functional recovery.

Consider combining the two only when the experimental design explicitly tests whether sleep-dependent recovery pathways and neurotrophin-dependent plasticity pathways interact. The combination is not automatically synergistic. It should be framed as a testable interaction hypothesis, not a default stack.

Molecular identity: where the divergence begins#

The structural and ancestral differences between DSIP and Semax are the foundation of every comparison that follows.

DSIP: the sleep-isolated nonapeptide#

DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was originally isolated from the cerebral venous blood of rabbits during induced delta-sleep states. The molecular weight is approximately 849 daltons as the free peptide. The sequence contains a tryptophan at the N-terminus and a glutamate at the C-terminus, with two glycine residues providing conformational flexibility in the mid-sequence.

DSIP's origin in sleep physiology is central to its research identity. It was not designed as a synthetic analogue of a known hormone; it was discovered as a naturally occurring factor that correlated with specific sleep stages. This discovery context means that DSIP's literature is tightly bound to sleep electrophysiology and neuroendocrine timing from the outset. Researchers who approach DSIP as though it were a generic anxiolytic or sedative miss this contextual anchor.

Semax: the ACTH-derived heptapeptide#

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, corresponding to ACTH(4-10) with a stabilising Pro-Gly-Pro tail. Its molecular weight is approximately 813 daltons as the free peptide. Unlike DSIP, Semax was deliberately engineered from a known pituitary hormone fragment, modified for metabolic stability while stripping away the classical endocrine activity of full-length ACTH.

Semax's origin in melanocortin and pituitary research gives it a mechanistic trajectory entirely different from DSIP. The ACTH heritage means that melanocortin receptor interactions, corticotropin biology, and neurotrophin regulation are all part of its research background. Where DSIP is a sleep factor, Semax is a neuroprotective derivative of a stress hormone.

Structural comparison#

Mechanisms of action: sleep physiology versus neurotrophin signalling#

The mechanistic gap between DSIP and Semax is the most important distinction in this comparison.

DSIP: sleep-phase modulation and neuroendocrine timing#

DSIP does not act through a single classical receptor in the way that a small-molecule drug might. The literature describes a network of interacting systems rather than a single high-affinity target.

Sleep architecture modulation. The original DSIP literature reported that intravenous or intracerebroventricular administration in rabbits increased the duration and amplitude of delta-wave sleep without proportionally increasing REM sleep or total sleep time. This selectivity is pharmacologically significant: it suggests that DSIP modulates the depth and restorative quality of specific sleep phases rather than globally depressing central nervous system activity. In research terms, DSIP is better described as a sleep-structure modulator than as a hypnotic.

HPA-axis and stress-response modulation. DSIP has been reported to influence corticotropin-releasing factor, adrenocorticotropic hormone, and cortisol dynamics in stress models. Some studies describe a normalising effect: DSIP reduces exaggerated stress-hormone responses without suppressing baseline endocrine function. This "buffering" profile is consistent with a compound that supports homeostatic recovery rather than driving a directional pharmacological push.

Endocrine and circadian interactions. DSIP has been examined for effects on growth hormone, prolactin, and luteinising hormone secretion. The endocrine literature is older and less replicated than the sleep literature, but the consistent theme is that DSIP influences the timing of hormone release in relation to sleep-wake transitions. Researchers interested in circadian-neuroendocrine cross-talk may find this literature relevant, though the mechanistic detail is thinner than for sleep architecture.

Temperature and metabolic effects. Some pre-clinical studies have reported that DSIP modulates body temperature and basal metabolic rate in a manner that correlates with sleep-state changes. These effects are not the primary research focus, but they add to the picture of DSIP as a compound that coordinates multiple physiological systems around sleep-dependent recovery.

Semax: BDNF/trkB, melanocortin, and CREB signalling#

Semax has a clearer primary mechanistic story than DSIP, though its biology is still multi-layered.

BDNF/trkB upregulation. The most widely cited Semax mechanism is increased brain-derived neurotrophic factor expression and TrkB receptor phosphorylation. A rat hippocampal study reported that a single intranasal Semax exposure increased BDNF protein, TrkB phosphorylation, BDNF mRNA, and TrkB mRNA, alongside improved conditioned-avoidance performance. This multi-level result gives Semax a stronger mechanistic anchor than DSIP possesses. The BDNF/trkB system is central to synaptic plasticity, learning, and neuronal survival.

Melanocortin signalling. Because Semax derives from ACTH, melanocortin receptor interactions are plausible and have been investigated. The melanocortin system includes five receptor subtypes with diverse central and peripheral roles. Semax does not behave as a classical ACTH hormone, but melanocortin-adjacent signalling may contribute to its effects on attention, stress response, and neuroprotection.

CREB and immediate-early gene activation. In cerebral ischemia models, Semax has been reported to increase active CREB in subcortical structures and to alter expression of immediate-early genes such as c-Fos. These transcriptional changes are consistent with a compound that promotes pro-survival and plasticity-related gene programmes after injury.

Dopamine and attention hypotheses. Semax has been proposed as a potential attention-deficit research tool based on reported effects on dopamine release and attention-like measures in rodent models. This literature distinguishes Semax from DSIP in a practically meaningful way: Semax is discussed in attention-recovery contexts, while DSIP is discussed in sleep-recovery contexts.

Comparison of mechanistic clarity#

Semax has a clearer primary mechanistic story — BDNF/trkB upregulation — supported by protein, phosphorylation, transcript, and behavioural data in the same study. DSIP's mechanism is more distributed: sleep-phase modulation, HPA-axis buffering, endocrine timing, and temperature regulation all appear in the literature, but no single study ties them together as coherently as the Semax BDNF paper does. For researchers who value a single pathway to build a protocol around, Semax offers a tighter target. For researchers interested in multi-system sleep and recovery physiology, DSIP's distributed mechanism may be the feature rather than the bug.

The evidence map: human, animal, and molecular#

Both DSIP and Semax have evidence bases that span human clinical reports, animal behavioural studies, and molecular experiments. The quality, geography, and focus of that evidence differ in ways that matter for protocol design.

Human clinical literature#

DSIP. The primary human data come from small studies in insomnia, narcolepsy, and withdrawal syndromes. Early European literature reported that DSIP administration improved subjective sleep quality, reduced sleep-onset latency, and normalised sleep-stage distribution in small cohorts. Some studies examined DSIP in alcohol and opiate withdrawal, reporting reduced withdrawal symptoms and improved sleep architecture. These data are old, small, and not replicated in large modern trials. They support mechanism-aware research; they do not support clinical validation in Canada.

Semax. The primary human data come from Russian clinical use in stroke recovery and cognitive impairment, with published proposals for attention-deficit applications. The stroke literature describes Semax administration in acute and subacute phases, with reported improvements in neurological scores and motor recovery. Like DSIP, these data are jurisdiction-specific, not replicated in large international trials, and not equivalent to Health Canada approval.

For both compounds, the human evidence is best treated as a signal that justifies further research, not as a basis for therapeutic claims or personal-use recommendations.

Animal behavioural models#

DSIP. The animal literature is concentrated in sleep electrophysiology and stress-recovery models. EEG studies in rabbits and rats report increased delta-wave activity, altered sleep-stage transitions, and changes in REM latency after DSIP administration. The stress literature includes corticosterone dynamics, behavioural despair models, and HPA-axis challenge studies. The breadth is narrower than Selank's literature but deeper in its specific domain: DSIP is one of the most studied peptides in sleep-phase research, but it has almost no cognitive or neuroprotection literature outside of sleep-dependent recovery contexts.

Semax. The animal literature is concentrated in neuroprotection and cognition-recovery models. Middle cerebral artery occlusion, ischemia-reperfusion, conditioned avoidance, and attention-like tasks dominate the published work. The concentration gives Semax a sharper experimental identity than DSIP, but it also means less diversity of model types. Researchers interested in sleep or circadian models will find far less Semax data than DSIP data.

Molecular and cellular work#

DSIP. The molecular literature for DSIP is thinner than for Semax. Some studies have examined DSIP binding to membrane fractions from rat brain, reporting low-affinity, high-capacity binding consistent with an endogenous modulator rather than a high-affinity agonist. The absence of a cloned DSIP receptor means that mechanistic research must proceed through physiological and behavioural endpoints rather than through receptor pharmacology. This is a limitation for researchers who require a clear molecular target, but it is not a fatal flaw for sleep-architecture or stress-recovery protocols.

Semax. The BDNF/trkB hippocampal study provides protein, phosphorylation, and transcript data in a single experiment, giving Semax a stronger molecular anchor. Additional papers have examined neurotrophin transcription in ischemic cortex and stress-response transcriptomics, producing a more coherent molecular picture than DSIP's distributed physiological effects.

Sleep and circadian models: DSIP's domain#

This is where DSIP most clearly distinguishes itself from Semax. The pre-clinical and clinical literature for DSIP is heavily weighted toward sleep architecture, delta-wave activity, and circadian-neuroendocrine timing.

In EEG-based sleep studies, DSIP has been reported to increase the proportion of time spent in slow-wave sleep, increase delta-wave amplitude, and reduce sleep-onset latency without increasing total sleep time proportionally. This profile is pharmacologically interesting because it suggests that DSIP deepens sleep rather than simply prolonging it. The distinction matters for researchers who are interested in sleep quality versus sleep quantity: a compound that increases deep sleep may produce different functional outcomes than a compound that increases total sleep duration.

The circadian literature adds another layer. DSIP has been reported to influence the timing of hormone secretion in relation to the sleep-wake cycle, including growth hormone, prolactin, and luteinising hormone. These effects are not the primary focus of most DSIP studies, but they suggest that DSIP may act as a coordinator of sleep-dependent physiological recovery rather than as a single-target sleep drug.

For Canadian researchers designing sleep, circadian, or stress-recovery protocols, DSIP is the natural starting point. The depth of published sleep data, the coherence with HPA-axis and endocrine mechanisms, and the human clinical signal in insomnia and withdrawal populations all point in the same direction. Semax has no meaningful sleep-architecture literature.

Neuroprotection and plasticity models: Semax's domain#

This is where Semax most clearly distinguishes itself from DSIP. The neuroprotection and stroke-recovery literature for Semax is substantially deeper and more focused than anything available for DSIP.

Experimental stroke models, including permanent and transient middle cerebral artery occlusion, are the backbone of the Semax neuroprotection literature. Multiple papers report reduced infarct volume, improved neurological scores, and altered molecular markers of inflammation and cell death. The BDNF/trkB mechanism provides a plausible unifying explanation: upregulation of neurotrophin signalling promotes neuronal survival, enhances synaptic plasticity, and supports recovery of function after ischemic injury.

The protein-expression study in transient MCAO is particularly useful because it does not rely on a single endpoint. Increases in active CREB, reductions in MMP-9, and decreases in active JNK together paint a picture of a compound that shifts the post-ischemic brain toward pro-survival and anti-inflammatory transcriptional programmes.

DSIP has essentially no published ischemia or stroke model data. Its neuroprotection potential, if any, would have to be inferred from the general sleep-recovery and stress-resilience literature rather than from direct injury models. For researchers designing neuroprotection or stroke-recovery protocols, Semax is the clear choice.

Stress recovery: contested but tilted toward DSIP#

Both DSIP and Semax are discussed in stress-recovery contexts, but the nature of that discussion differs.

DSIP stress recovery. The primary stress-recovery claims for DSIP come from HPA-axis modulation, corticosterone normalisation, and withdrawal-state studies. In alcohol and opiate withdrawal models, DSIP has been reported to reduce the severity of withdrawal symptoms and to normalise sleep disturbances that accompany withdrawal. The mechanism is typically framed as homeostatic buffering: DSIP supports the return of physiological systems to baseline after challenge, rather than driving a specific pharmacological effect.

Semax stress recovery. The primary stress-recovery claims for Semax come from BDNF/trkB upregulation in hippocampus and cortex, coupled with improved conditioned-avoidance performance after stress challenge. The mechanism is more directly plasticity-oriented: increasing neurotrophin signalling to enhance synaptic resilience and recovery after stress. The melanocortin literature also supports a stress-recovery interpretation, because melanocortin peptides are involved in HPA-axis regulation.

The practical difference is that DSIP's stress-recovery effects are most evident in sleep-dependent and endocrine-dependent models, while Semax's stress-recovery effects are studied through neurotrophin and plasticity mechanisms. A researcher interested in stress recovery through sleep architecture and HPA-axis timing should favour DSIP. A researcher interested in stress recovery through synaptic plasticity and neurotrophin signalling should favour Semax.

Pharmacokinetics, route, and stability considerations#

Formal pharmacokinetic data for both DSIP and Semax in humans are extremely limited.

DSIP. As a nonapeptide of approximately 849 daltons, DSIP is small enough to be cleared renally with a relatively short functional half-life. Intranasal administration has been explored in parts of the literature, raising the possibility of nose-to-brain delivery, but species-specific nasal anatomy complicates translation. Subcutaneous injection is the standard research route when systemic exposure is desired. DSIP contains a tryptophan residue, which is susceptible to oxidation under light and oxidative conditions. Lyophilised DSIP should be stored protected from light and moisture.

Semax. As a heptapeptide of approximately 813 daltons, Semax has similar pharmacokinetic expectations: renal clearance, short half-life, and limited oral bioavailability. Intranasal administration is common in the Russian clinical studies, but the same translational caveats apply. The methionine residue in Semax is susceptible to oxidation, and the histidine residue can coordinate metal ions under certain conditions. Subcutaneous injection is the standard research route for controlled systemic exposure.

For both compounds, the lack of formal human pharmacokinetic studies means that dosing in research protocols should be guided by the published animal literature rather than by clinical PK parameters.

Sourcing and analytical quality for short peptides#

The small size of DSIP and Semax creates the same dangerous paradox as Selank and Semax: easier to synthesise, easier to synthesise poorly.

For both compounds, the minimum supplier package should include:

1. Batch-specific HPLC purity. A chromatogram showing the principal peak, method conditions, and integration.
2. Mass spectrometry identity confirmation. For DSIP: approximately 849 Da (free peptide). For Semax: approximately 813 Da (free peptide).
3. Clear vial mass and fill tolerance.
4. Endotoxin and microbial documentation.
5. Storage and shipping guidance. DSIP requires light protection. Both require moisture control.
6. RUO-compliant language.

Lynx Labs lists both DSIP and Semax in the cognitive category, with batch-specific COA documentation. Northern Compound points readers toward Lynx Labs as a domestic Canadian research-source starting point based on batch documentation, domestic fulfilment, and attribution-transparent outbound links.

For the broader framework on evaluating Canadian peptide suppliers, see the Northern Compound research peptides Canada buyer's guide. Reconstitution principles for both compounds are detailed in the reconstitution guide.

Choosing between DSIP and Semax: a decision framework#

After reviewing the full comparison, the practical differentiators for Canadian research protocol design can be summarised as follows.

Favour DSIP for research protocols involving: sleep architecture and delta-wave modulation; circadian-rhythm and neuroendocrine timing studies; HPA-axis dynamics and corticosterone normalisation models; alcohol or opiate withdrawal recovery research; stress-recovery protocols that depend on sleep-dependent homeostasis; or any research question that builds on the sleep-isolated peptide literature.

Favour Semax for research protocols involving: cerebral ischemia or stroke-recovery models; neuroprotection endpoint studies; BDNF/trkB or neurotrophin-signalling research; melanocortin-pathway or attention-recovery experiments; models of plasticity-driven learning or memory after injury; or any research question that builds on the ACTH-derived, neurotrophin-centred literature.

Consider running both in parallel only when the experimental design explicitly tests whether sleep-dependent recovery pathways and neurotrophin-dependent plasticity pathways interact. A combined protocol should include individual compound arms, a vehicle control, and appropriate behavioural and molecular endpoints. The combination is not automatically synergistic.

Neither compound should be chosen for human self-administration outside of a formally approved clinical trial. The evidence base remains overwhelmingly pre-clinical and jurisdiction-specific.

References and further reading#

• Schoenenberger G.A. et al. "Characterization of a delta-electroencephalogram (-sleep)-inducing peptide." Proceedings of the National Academy of Sciences (1977). PubMed.
• Kastin A.J. et al. "DSIP: a sleep-inducing peptide." Life Sciences (1984). PubMed.
• Schneider-Helmert D. "Effects of DSIP on sleep and daytime performance." Psychopharmacology (1987). PubMed.
• Graf M.V. et al. "Delta-sleep-inducing peptide (DSIP): a review." Neuroscience and Biobehavioral Reviews (1985). PubMed.
• Dolotov O.V. et al. "Semax, an analogue of adrenocorticotropin (4-10), binds selectively and increases BDNF and TrkB expression in rat hippocampus." Neurochemical Research (2006). PubMed.
• Khomutov G.B. et al. "The Effect of Semax on the Expression of Proteins Associated with Inflammation and Blood–Brain Barrier Integrity in Rat Brain after Transient Ischemia." Pharmaceuticals (2021). PubMed.
• Dmitrieva V.G. et al. "The peptide Semax affects the expression of genes related to the neurotrophin system of the brain under conditions of experimental focal ischemia." Molecular Biology (2010). PMC full text.
• Filippenkov I.B. et al. "Melanocortin Derivatives in a Rat Model of Acute Restraint Stress: Behavioral and Transcriptomic Analysis." International Journal of Molecular Sciences (2021). PMC full text.
• De Wied D. et al. "Peptides that affect central nervous system function: a possible new class of drugs." Current Pharmaceutical Design (2006). PubMed.